Machine Learning\u2010Enabled Drug\u2010Induced Toxicity Prediction

Aim: The majority of machine learning (ML) models in healthcare are built on retrospective data, much of which is collected without explicit patient consent for use in artificial intelligence (AI) and ML applications. The primary aim of this study was to evaluate whether clinicians and scientific researchers themselves consent to provide their own data for the training of ML models. Materials and Methods: This survey was conducted through an anonymous online survey, utilizing platforms such as Telegram, LinkedIn, and Viber. The target audience comprised specific international groups, primarily Russian, German, and English-speaking, of clinicians and scientific researchers. These participants ranged in their levels of expertise and experience, from beginners to veterans. The survey centered on a singular, pivotal question: “Do You Consent to the Use of Your Biological and Private Data for Training Machine Learning and AI Models?” Respondents had the option to choose from three responses: “Yes” and “No”. Results: The survey was conducted in January 2024. A total of 119 unique and verified individuals participated in the survey. The results revealed that only 50% of respondents (63 persons) expressed consent to provide their own data for the training of ML and AI models. Conclusion: In the development of ML and AI models, particularly open-source ones, it is crucial to ascertain whether participants are willing to provide their private data. While ML algorithms can transform the nature of data, it is important to remember that the primary owner of this data is the individual. Our findings show that in 50% of the cases, even participants from scientific research and clinical backgrounds – individuals typically accountable for ensuring data quality in AI and ML model development – do not consent to the use of their data in AI and ML settings. This highlights the need for more stringent consent processes and ethical considerations in the utilization of personal data in AI and ML research.

Artificial intelligence for patient scheduling in the real-world health care setting: A metanarrative review

Study question Can a machine learning (ML) model, developed using modern neural network architecture produce comparable annotation data; utilisable for algorithmic outcome prediction, to manual time-lapse annotations? Summary answer The model automatically annotated unseen embryos with comparable results to manual methods, generating morphokinetic data to enable comparably predictive outputs from an embryo selection algorithm. What is known already The application of artificial intelligence across healthcare industries, including fertility, is increasing. Several ML models are available that seek to generate or analyse embryo images and morphokinetic data, and to determine embryo viability potential. Along with photographic images, the use of time-lapse in IVF laboratories has amassed numeric data, resulting predominantly from annotated manual assessment of images over time. Embryo annotation practice is variable in quality, can be subjective and is time-consuming; commonly taking several minutes per embryo. The development of rapid, accurate automatic annotation would represent a significant time-saving as well as an increase in reproducibility and accuracy. Study design, size, duration Multicentre quality assured annotation data from 63,383 time-lapse monitored embryos (EmbryoScope®), comprising over 400 million individual images, were used to train a ML model to automatically generate morphokinetic annotations. Data was derived from 8 UK clinics within a cohesive group between 2012-2021. Accuracy was assessed using 900 unseen embryos (with live birth outcome) by comparing the output of an established in-house, prospectively validated embryo selection model when the input was either ML-automated, or manual annotations. Participants/materials, setting, methods Multi-focal plane images were processed on the Azure cloud (Microsoft) and resampled to 300x300 pixels. A Laplacian-based focal stacking algorithm merged frames into a single image. The model consisted of an EfficientNetB4 Convolutional Neural Network classifier to extract features and classify the stage of embryo images. A Temporal Convolutional Network interpreted a time-series of image features; producing annotations from pronuclear fading through to blastocyst. Soft localisation loss function used QA data to integrate annotation subjectivities. Main results and the role of chance The ML model rapidly and automatically generated annotations. Efficacy and comparability of the ML model to automate reliable, utilisable annotations was demonstrated by comparison with manual annotation data and the ML model’s ability to auto-generate annotations which could be used to predict live birth by providing annotation data to an established, validated in house embryo selection model. Live birth-predictive capability was measured, and benchmarked against manual annotation, using the area under the receiver operating characteristic curve (AUC). When tested on time-lapse images, collected from pronuclear fading to full blastulation, representing 900 previously unseen, transferred blastocysts where live birth outcomes were blinded, the in-house developed auto-annotation ML model resulted in an AUC of 0.686 compared with 0.661 for manual annotations, for live birth prediction. Auto annotation using the developed model took only milliseconds to complete per embryo. The developed auto-annotation model, built and tested on large data, is considered suitable for productionisation with the aim of being validated and integrated into an application to support IVF laboratory practice. Limitations, reasons for caution Whilst this model was trained to recognise key morphokinetic events, there are other morphokinetic variables that may be useful in the prediction of live birth and further improve embryo selection, or deselection, ability. Akin to manual interpretation, some embryos may fail to be annotated or need second opinion. Wider implications of the findings There is increasing evidence supporting the application of ML to utilise big data from time-lapse imaging and fertility care generally. Whilst promising benefits to IVF clinics and patients, responsible use of data is required alongside large high-quality datasets, and rigorous validation, to ensure safe and robust applications. Trial registration number N/A

Chemical heuristics have been fundamental to the advancement of chemistry and materials science. These heuristics are typically established by scientists using knowledge and creativity to extract patterns from limited datasets. Machine learning offers opportunities to perfect this approach using computers and larger datasets. Here, we discuss the relationships between traditional heuristics and machine learning approaches. We show how traditional rules can be challenged by large-scale statistical assessment and how traditional concepts commonly used as features are feeding the machine learning techniques. We stress the waste involved in relearning chemical rules and the challenges in terms of data size requirements for purely data-driven approaches. Our view is that heuristic and machine learning approaches are at their best when they work together.

Artificial intelligence and Machine Learning approaches in sports: Concepts, applications, challenges, and future perspectives

Pharmacovigilance, the science of monitoring drug safety, plays a crucial role in identifying and mitigating adverse drug reactions (ADRs). However, underreporting in pharmacovigilance systems—estimated to have a median rate of 94 %—poses a significant threat to patient safety by hindering the detection of safety signals. The need to address these gaps is paramount, especially with the rising complexity of healthcare data. The advent of artificial intelligence (AI) and big data technologies offers promising solutions to overcome the limitations of traditional pharmacovigilance methods.The application of AI and machine learning (ML) technologies, including natural language processing (NLP) and deep learning, has the potential to revolutionize drug safety monitoring by automating the detection of ADRs from diverse data sources, such as electronic health records (EHRs), spontaneous reporting systems, and social media. These tools can process unstructured data and uncover patterns not easily identifiable through conventional approaches. Additionally, AI can enable real-time pharmacovigilance, which is especially critical in an era of increasing polypharmacy and diverse patient populations. AI-driven models are being utilized to detect drug-drug interactions (DDIs), predict ADRs, and enhance the overall efficiency of pharmacovigilance processes.Despite these advancements, several challenges remain. The performance of AI models is heavily dependent on the quality and quantity of data available. Inadequate or poorly curated datasets can lead to inaccurate ADR detection, particularly in resource-limited settings. Moreover, the heterogeneity of data sources necessitates robust AI models capable of integrating various types of data while ensuring accurate and reliable outputs. There is also a pressing need to address the transparency and explainability of AI models, as the opaque decision-making processes of current algorithms often impede their acceptance among pharmacovigilance professionals.Future directions must focus on improving the quality and standardization of datasets, advancing NLP techniques for better interpretation of clinical narratives, and developing explainable AI models. Regulatory frameworks should evolve to support AI deployment in pharmacovigilance, ensuring the establishment of best practices for AI implementation and the creation of large-scale, publicly available training datasets.Additionally, AI models should go beyond correlation-based approaches by integrating causal inference techniques, which will allow for a more accurate understanding of the relationship between drugs and ADRs. Human oversight will still be required to validate AI findings, but ongoing efforts to improve the robustness of AI systems will reduce dependency on manual interventions and scale the use of AI in pharmacovigilance.The integration of AI and big data in pharmacovigilance has the potential to transform drug safety monitoring, addressing many of the challenges posed by increasing data complexity and the need for real-time analysis. As these technologies continue to evolve, they promise to make pharmacovigilance more efficient, accurate, and comprehensive, thereby improving patient safety and rational drug use.

Photo by Josh Riemer on Unsplash
 Introduction
 With the rapid advancements in neurotechnological machinery and improved analytical insights from machine learning in neuroscience, the availability of big brain data has increased tremendously. Neurological health research is done using digitized brain data.[1] There must be adequate data governance to secure the privacy of subjects participating in brain research and treatments. If not properly regulated, the research methods could lead to significant breaches of the subject’s autonomy and privacy. This paper will address the necessity for neuroprotection laws, which effectively govern the use of big brain data to ensure respect for patient privacy and autonomy.
 Background
 Artificial intelligence and machine learning can be integrated with neuroscience big brain data to drive research studies. This integrative technology allows patterns of electrical activity in neurons to be studied in detail.[2]Specifically, it uses a robotic system which can reason, plan, and exhibit biologically intelligent behavior. Machine learning is a method of computer programming where the code can adapt its behavior based on big brain data.[3] The big brain data is the collection of large amounts of information for the purpose of deciphering patterns through computer analysis using machine learning.[4] The information that these technologies provide is extensive enough to allow a researcher to read a patient’s mind. AI and machine learning technologies work by finding the underlying structure of brain data, which is then described by patterns known as latent factors, eventually resulting in an understanding of the brain’s temporal dynamics.[5]
 Through these technologies, researchers are able to decipher how the human brain computes its performances and thoughts. However, due to the extensive and complex nature of the data processed through AI and machine learning, researchers may gain access to personal information a patient may not wish to reveal. From a bioethical lens, tensions arise in the realm of patient autonomy. Patients are not able to control the transmission of data from their brains that is analyzed by researchers. Governing brain data through laws may enhance the extent of patient privacy in the case where brain data is being used through AI technologies.[6] A responsible approach to governing brain data would require a sophisticated legal structure.
 Analysis
 Impact on Patient Autonomy and Privacy 
 In research pertaining to big brain data, the consent forms do not fully cover the vast amounts of information that is collected. According to research, personal data has become the most sought out commodity to provide content to corporations and the web-based service industry. Unfortunately, data leaks that release private information frequently occur.[7] The storage of an individual’s data on technologies accessible on the internet during research studies makes it vulnerable to leaks, jeopardizing an individual’s privacy. These data leaks may cause the patient to be identified easily, as the degree of information provided by AI technologies are personalized and may be decoded through brain fingerprinting methods.[8]
 There has been an extensive growth in the development and use of AI. It is efficient in providing information to radiologists who diagnose various diseases including brain cancer and psychiatric disease, and AI assists in the delivery of telemedicine.[9] However, the ethical pitfall of reduced patient autonomy must be addressed by analyzing current AI technologies and creating more options for patient preference in how the data may be used. For instance, facial recognition technology[10] commonly used in health care produces more information than listed in common consent forms, threatening to undermine informed consent. Facial recognition software collects extensive data and may disclose more information than a person would prefer to provide despite being a useful tool for diagnosing medical and genetic conditions.[11] In addition, people may not be aware that their images are being used to generate more clinical data for other purposes. It is difficult to guarantee the data is anonymized. Consent requirements must include informing people about the complexity of the potential uses of the data; software developers should maximize patient privacy.[12] Furthermore, there is a “human element” in the use of AI technologies as medical providers control the use and the extent to which data is captured or accessed through the AI technologies.[13] People must understand the scope of the technology and have clear communication with the physician or health care provider about how the medical information will be used. 
 Existing Laws for Brain Data Governance 
 A strict system of defined legal responsibilities of medical providers will ensure a higher degree of patient privacy and autonomy when AI technologies and data from machine learning are used. Governing specific algorithmic data is crucial in safeguarding a patient’s privacy and developing a gold standard treatment protocol following the procurement of the information.[14] Certain AI technologies provide more data than others, and legal boundaries should be established to ensure strong performance, quality control, and scope for patient privacy and autonomy. For instance, currently AI technologies are being used in the realm of intensive neurological care. However, there is a significant level of patient uncertainty about how much control patients have over the data’s uses.[15] Calibrated legal and ethical standards will allow important brain data to be securely governed and monitored.
 Once brain signals are recorded and processed from one individual, the data may be merged with other data in Brain Computer Interface Technology (BCI).[16] To ensure a right and ability to retrieve personal data or pull it from the collection, specific regulations for varying types of data are needed.[17] The importance of consent and patient privacy must be considered through giving patients a transparent view of how brain data is governed.[18] The legal system must address discriminatory issues and risks to patients whose data is used in studies. Laws like the General Data Protection Regulation (GDPR) and the California Consumer Privacy Protection Act (CCPA) can serve as effective models to protect aggregated data. These laws govern consumer information and ensure the compliance when personal data is collected.[19] California voters recently approved expansion of the CCPA to health data. The Washington Privacy Act, which would have provided rights to access, change, and withdraw personal data, failed to pass. Other states should improve privacy as well,[20] although a federal bill would be preferable. Scientists at the Heidelberg Academy of Sciences argue for data security to be governed in a manner that balances patient privacy and autonomy with the commercial interests of researchers.[21] The balance could be achieved through privacy protections like those in the Washington Privacy Act. Although the Health Insurance Portability and Accountability Act (HIPAA) provides an overall framework to deter the likelihood of dangers to patient protection and privacy, more thorough laws are warranted to combat pervasive data transfer and analysis that technology has brought to the health care industry.[22] Breaches of patient privacy under current HIPAA regulations include releasing patient information to a reporter without their consent and sending HIV data to a patient’s employer without consent.[23] HIPAA does not cover information being shared with outside contractors who do not have an agreement with technology companies to keep patient data confidential. HIPAA regulations also do not always address blatant breaches on patient data confidentiality.[24] Patients must be provided with methods to monitor the data being analyzed to be able to view the extent of private information being generated via AI technologies. In health research, the medical purposes of better diagnosis, earlier detection of diseases, or prevention are ethical justifications for the use of the data if it was collected with permission, the person understood and approved the uses of the data, and the data was deidentified.
 A standard governance framework is required in providing the fairest system of care to patients who allow their brain data to be examined. Informed consent in the neuroscience field could reaffirm the privacy and autonomy of patients by ensuring that they understand the type of information collected. Laws also could protect data after a patient’s death. Malpractice in the scope of brain data could give people a cause of action critical in safeguarding patient’s rights. Data breach lawsuits will become common but generally do not cover deidentified data that becomes part of big data collection. A more synchronized approach to the collection and consent process will encourage an understanding of how big data is used to diagnose and treat patients. Some altruistic people may even be more likely to consent if they know the largescale data collection is helpful to treat and diagnose people. Others should have the ability to opt out of sharing neurological data, especially when there is not certainty surrounding deidentification.[25]
 Conclusion
 Artificial intelligence and machine learning technologies have the potential to aid in the diagnosis and treatment of people globally by extracting and aggregating brain data specific to individuals. However, the secure use of the data is necessary to build trust between care providers and patients, as well as in balancing the bioethical principles of beneficence and patient autonomy. We must ensure the highest quality of care to patients, while protecting their privacy, informed consent, and clinical trust. More sophis

Systematic Review of Currently Available Predictive Machine Learning Models for Multiple Myeloma

Machine learning-based water quality prediction using octennial in-situ Daphnia magna biological early warning system data

Machine Learning Can Accurately Predict Overnight Stay, Readmission, and 30-Day Complications Following Anterior Cruciate Ligament Reconstruction

Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, contributing to a heavier global health burden. Non-invasive diagnostic tools developed using machine learning (ML) and deep learning (DL), two representative artificial intelligence algorithms, are increasingly being explored for MASH and its related fibrosis assessment. This study aimed to compare the diagnostic performance of different ML and DL models and identify the top-performing models for diagnosing MASH and associated liver fibrosis. A systematic review and meta-analysis were conducted across PubMed, Web of Science, Embase and Cochrane Library from inception to May 18, 2025. Pooled area under the receiver operator characteristic curve (AUROC) values with 95 % confidence interval (CI) were calculated. Accuracy, specificity, sensitivity, positive predictive values, and negative predictive values were also recorded. Of 4,314 studies initially identified, 106 met the inclusion criteria, with 35 studies (ML: n=28; DL: n=7) providing data for analysis. Logistic Regression and Neural Network are the most commonly algorithms applied in ML and DL, respectively. The pooled AUROCs for diagnosing MASH were 0.833 (95 %CI: 0.806-0.860) for ML models and 0.841 (95 %CI: 0.782-0.900) for DL models. Light Gradient Boosting Machine (LightGBM) and ResNet50 were the best-performing models for diagnosing MASH within ML and DL algorithms, respectively, achieving corresponding AUROCs of 0.920 (95 %CI: 0.916-0.924) and 0.960 (95 %CI: 0.951-0.969). For fibrosis diagnosis, ML models had a pooled AUROC of 0.826 (95 %CI: 0.792-0.860), with Categorical Boosting (CatBoost) achieving the highest AUROC of 0.960 (95 %CI: 0.950-0.970). DL models yielded the pooled AUROC of 0.875 (95 %CI: 0.816-0.934) for fibrosis diagnosis. Both ML and DL models demonstrated strong diagnostic performance for MASH and liver fibrosis, with DL achieving marginally higher AUROCs. AI-driven approaches show promise in MASLD management.

The objective of this document is to identify the most accurate machine learning (ML) models for predicting the value of a real estate property, based on a systematic literature review (SLR). It was conducted on research published between 2022 and 2023 that analyzed the accuracy of ML models in real estate valuation. Information was extracted regarding the ML models used, the databases employed, and the models highlighted for their accuracy. A variety of ML models used in real estate valuation were identified, including Random Forest (RF), XGBoost, Gradient Boosting Machine (GBM), Linear Regression (LR), and Lasso Regression. RF and LR models stood out as the most accurate in the analyzed research, showing that the accuracy of ML models varies depending on the database, property characteristics, and valuation context. It was concluded that ML models like RF and LR are promising tools for improving the accuracy of real estate valuation. Additionally, the choice of the best ML model depends on factors such as the database, property characteristics, and specific valuation objectives. Further research is needed on the application of ML in real estate valuation, considering aspects such as model interpretability and the real estate market context.

Summary A meticulous interpretation of steady-state or unsteady-state relative permeability (Kr) experimental data is required to determine a complete set of Kr curves. In this work, different machine learning (ML) models were developed to assist in a faster estimation of these curves from steady-state drainage coreflooding experimental runs. These ML algorithms include gradient boosting (GB), random forest (RF), extreme gradient boosting (XGB), and deep neural network (DNN) with a main focus on and comparison of the two latter algorithms (XGB and DNN). Based on existing mathematical models, a leading-edge framework was developed where a large database of Kr and capillary pressure (Pc) curves were generated. This database was used to perform thousands of coreflood simulation runs representing oil-water drainage steady-state experiments. The results obtained from these simulation runs, mainly pressure drop along with other conventional core analysis data, were used to estimate analytical Kr curves based on Darcy’s law. These analytically estimated Kr curves along with the previously generated Pc curves were fed as features into the ML model. The entire data set was split into 80% for training and 20% for testing. The k-fold cross-validation technique was applied to increase the model’s accuracy by splitting 80% of the training data into 10 folds. In this manner, for each of the 10 experiments, nine folds were used for training and the remaining fold was used for model validation. Once the model was trained and validated, it was subjected to blind testing on the remaining 20% of the data set. The ML model learns to capture fluid flow behavior inside the core from the training data set. In terms of applicability of these ML models, two sets of experimental data were needed as input; the first was the analytically estimated Kr curves from the steady-state drainage coreflooding experiments, while the other was the Pc curves estimated from centrifuge or mercury injection capillary pressure (MICP) measurements. The trained/tested model was then able to estimate Kr curves based on the experimental results fed as input. Furthermore, to test the performance of the ML model when only one set of experimental data is available to an end user, a recurrent neural network (RNN) algorithm was trained/tested to predict Kr curves in the absence of Pc curves as an input. The performance of the three developed models (XGB, DNN, and RNN) was assessed using the values of the coefficient of determination (R2) along with the loss calculated during training/validation of the model. The respective crossplots along with comparisons of ground truth vs. artificial intelligence (AI)-predicted curves indicated that the model is capable of making accurate predictions with an error percentage between 0.2% and 0.6% on history-matching experimental data for all three tested ML techniques. This implies that the AI-based model exhibits better efficiency and reliability in determining Kr curves when compared to conventional methods. The developed ML models by no means replace the need to conduct drainage coreflooding or centrifuge experiments but act as an alternative to existing commercial platforms that are used to interpret experimental data to predict Kr curves. The two main advantages of the developed ML models are their capability of predicting Kr curves within a matter of a few minutes as well as with limited intervention from the end user. The results also include a comparison between classical ML approaches, shallow neural networks, and DNNs in terms of accuracy in predicting the final Kr curves. The research presented here is an extension of the state-of-the-art framework proposed by Mathew et al. (2021). However, the two main aspects of the current study are the application of deep learning for the prediction of Kr curves and the application of feature engineering. The latter not only reduces the training/testing time for the ML models but also enables the end user to obtain the final predictions with the least set of experimental data. The various models discussed in this research work currently focus on the prediction of Kr curves for drainage steady-state experiments; however, the work can be extended to capture the imbibition cycle as well.

Industry 4.0 has brought about a significant transformation in manufacturing by merging the digital and physical systems. It introduced innovations such as Internet of Things (IoT), Big Data, Artificial Intelligence (AI), and automation into industrial processes to promote the concept of smart manufacturing. Our current research focuses on creating methodologies for effectively using data in manufacturing through AI and Machine Learning (ML). Many US manufacturers, particularly Small to Medium Manufacturers (SMM), struggle to utilize ML due to financial constraints or a shortage of data science expertise. While Industry 4.0 emphasizes automation, Industry 5.0 introduces the idea of human-machine collaboration, where Industry 4.0 technology enhances human productivity using technologies like IoT and Big Data with an emphasis on trust as a key factor in their cooperation. This research concentrates on building trustworthy ML models that can be easily developed by SMM's for democratized AI, a central aspect of Industry 5.0. This involves developing interpretable ML models capable of explaining their decision-making processes by employing Explainable AI (XAI) concepts for interpretation. Subsequently, this work leverages the insights from XAI to improve ML performance through the domain manufacturing knowledge. By leveraging the aforementioned research thrusts, the final outcome of this research is a framework that establishes both trustworthy and generalizable ML models for SMMs.

Artificial intelligence (AI) is reshaping neurosurgery, offering unprecedented opportunities to enhance diagnostics, personalize treatment, and predict outcomes. At the heart of this transformation is the ability to effectively harness big data (BD) within the electronic medical record. Understanding these data structures is essential for making sense of the vast volumes of information generated in modern neurosurgical practice. Equally important are the machine learning (ML) models driving these advancements. From supervised learning and convolutional neural networks to generative AI, these tools are already making a mark in areas such as brain tumor segmentation and spine surgery outcome predictions. Their versatility highlights the potential of ML to complement clinical expertise and streamline decision-making in neurosurgery. However, adopting BD and ML also brings ethical challenges that cannot be ignored. Bias in algorithms threatens to reinforce health disparities, whereas concerns about data privacy demand vigilance in handling sensitive patient information. In addition, the question of liability looms large as ML increasingly influences clinical decisions. The aim of the study was to provide a roadmap for neurosurgeons navigating the evolving intersection of BD, ML, and ethical responsibility in the AI era.